SC: Absence of Independent Witnesses is Not Fatal if Injured Eyewitness Testimony is Sterling  ||  Supreme Court: Prosthetic Limb Costs Must Be Compensated To Restore Victims’ Dignity  ||  Supreme Court: Probate Can be Revoked For Non-Impleadment of Parties and Suppression of Facts  ||  SC: Plaint Cannot be Rejected For Valuation or Court Fee Defects Without Chance to Rectify  ||  SC Rules Government Grants Act Overrides Rent Law, Sets Aside Eviction Proceeding Against Union Govt  ||  SC: Civil Court Has No Jurisdiction in Boundary Dispute Between Maharashtra Panchayat & Municipality  ||  Allahabad HC: Two Criminal Cases Insufficient to Label a Person as 'Goonda' and Harm Reputation  ||  Bom HC: Sprinkling Mustard Without Ill Intent Before a House is Not an Offence under Black Magic Act  ||  J&K&L HC: Preventive Detention Invalid When Based on Speculative Fear of Election Disturbance  ||  Bombay High Court: POSH Act Penalises False Complaints by Women But Not Those Who Instigate Them    

CCI approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.- (Press Information Bureau) (16 Mar 2022)

MANU/PIBU/0878/2022

MRTP/ Competition Laws

The Competition Commission of India (CCI) approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.

The proposed combination pertains to the proposed acquisition of minority stake in Micro Life Sciences Private Limited (Micro Life/ Target) by South Elm Investments B.V. (SEI/ Acquirer).

SEI is an investment holding company incorporated under the laws of Netherlands. The shareholders of SEI are certain private equity funds managed by Warburg Pincus LLC.

Target is a company incorporated in India, which is primarily engaged in the following business activities in India along with subsidiaries: manufacture and sale of (a) medical devices in various categories such as stents, Percutaneous Transluminal Coronary Angioplasty catheters, heart valves, orthopedic implants, and endo-surgery products (such as sutures, staplers, meshes and intrauterine devices); (b) in-vitro diagnostics analyzers and reagents; and (c) over the counter (OTC) products like products COVID self-test kits and pregnancy test kits, in India. The Target (through its subsidiaries) is engaged in the B2C sale of certain specialized medical devices (such as surgical robots and ultrasonic energy devices) to hospitals and has research and development (R&D) facilities for in-vitro diagnostic, orthopedic, endo-surgery and cardiovascular solutions.

Tags : ACQUISITION   APPROVAL   MINORITY STAKE  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved